ImmunoGen Inc.

NASDAQ: IMGNHealthcare / Biotechnology / USA
2.73-0.1200-4.21%Vol 966 9581Y Perf -69.69%
Aug 20th, 2019 16:00
BID2.70 ASK2.76
Open2.83 Previous Close2.85
Pre-Market- After-Trading2.70
 - -%  -0.03 -1.10%
Target Price
3.00 
Analyst Rating
Moderate Buy 2.50
Potencial %
9.89 
Finscreener Ranking
★★★+ —    -
Insiders Trans % 3/6/12M
-/-/-50 
Value Ranking
★★+ —    -
Insiders Value % 3/6/12M
-/-/19 
Growth Ranking
★★ —    -
Insiders Shares Cnt. % 3/6/12M
-/-/34 
Income Ranking
 —    -
Market Cap (mil)409 
Earnings Rating
Strong Buy
Price Range Ratio 52wk %
11.27 
Earnings Date
2nd Aug 2019

Today's Price Range

2.682.86

52wk Range

1.7610.37

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-3.53%
1 Month
17.17%
3 Months
40.00%
6 Months
-50.90%
1 Year
-69.69%
3 Years
-9.60%
5 Years
-76.24%
10 Years
-63.65%

Name / TickerPriceChg.Chg.%
IMGN2.73-0.1200-4.21
AAPL210.610.26000.12
GOOG1 182.69-15.7600-1.32
MSFT137.26-1.1500-0.83
XOM69.03-0.4200-0.60
WFC44.68-0.5700-1.26
JNJ130.60-1.6500-1.25
FB183.81-2.3600-1.27
GE8.38-0.2900-3.34
JPM107.31-1.3800-1.27
Earnings HistoryEstimateReportedSurprise %
Q02 2019-0.32-0.299.38
Q01 2019-0.31-0.303.23
Q04 2018-0.33-0.2815.15
Q03 2018-0.34-0.318.82
Q02 2018-0.29-0.30-3.45
Q01 2018-0.27-0.30-11.11
Q04 2017-0.07-0.10-42.86
Q03 2017-0.28-0.37-32.14
Earnings Per EndEstimateRevision %Trend
9/2019 QR-0.1917.39Positive
12/2019 QR-0.1722.73Positive
12/2019 FY-0.962.04Positive
12/2020 FY-0.5532.93Positive
Next Report Date-
Estimated EPS Next Report-0.32
Estimates Count7
EPS Growth Next 5 Years %-
Volume Overview
Volume966 958
Shares Outstanding (in ths.)149 885
Trades Count5 346
Dollar Volume3 901 676
Avg. Volume3 388 243
Avg. Weekly Volume1 281 184
Avg. Monthly Volume2 156 971
Avg. Quarterly Volume2 896 531
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (37.50 %)
3 (37.50 %)
3 (37.50 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
4 (50.00 %)
4 (50.00 %)
4 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (12.50 %)
1 (12.50 %)
1 (12.50 %)
RatingModerate Buy
2.50
Moderate Buy
2.50
Moderate Buy
2.50

ImmunoGen Inc.

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have licensed limited rights to use the ADC technology in their therapies.

CEO: Mark J. Enyedy

Teplephone: +1 781 895-0600

Address: 830 Winter Street, Waltham 02451, MA, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

67%33%

Bearish Bullish

87%13%

Bearish Bullish

69%31%

News